Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Amneal Pharmaceuticals, Inc. (AMRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M | $526.2M | $597.5M |
| Research & development | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M | $179.9M | $188.0M | $194.2M | $171.4M | $179.0M |
| Operating income | $394.1M | $249.3M | $204.4M | −$94.9M | $152.7M | $91.2M | −$248.7M | −$19.7M | $245.1M | $284.9M |
| EBITDAderived | $617.7M | $485.5M | $433.8M | $145.3M | $386.1M | $326.5M | −$41.4M | $188.7M | $360.1M | $317.9M |
| Net income | $72.1M | −$116.9M | −$84.0M | −$270.6M | $13.2M | $67.8M | −$603.6M | −$19.7M | $0 | $0 |
| Basic EPSper diluted share | $0.23 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.62 | -$2.74 | -$0.16 | — | — |
| Diluted EPSper diluted share | $0.22 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.61 | -$2.74 | -$0.16 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | Autor Deborah M.Director | SellClass A Common Stock | 34.8K | $12.94 | $450.6K | 93.7K |
| Nov 17, 2025Form 4 | Nark Ted CDirector | SellClass A Common Stock | 50.0K | $11.72 | $586.0K | 291.0K |
| Nov 12, 2025Form 4 | Shah NikitaExecutive Vice President | SellClass A Common Stock | 131.9K | $11.92 | $1.57M | 146.4K |
| Aug 27, 2025Form 4 | Kiely JohnDirector | SellClass A Common Stock | 32.0K | $9.23 | $295.4K | 225.4K |
| Aug 25, 2025Form 4 | Shah NikitaExecutive Vice President | SellClass A Common Stock | 6.3K | $9.50 | $60.2K | 146.4K |